New study: Patients more likely to stick with Wegovy compared to older weight loss drugs
According to a new study, patients are more likely to continue prescribed use of Novo Nordisk’s obesity drug, Wegovy, than patients using older products with the same indication.
40% of patients who received a prescription for Novo Nordisk’s Wegovy to treat obesity in 2021 or 2022 were still taking it a year later, which is more than three times higher than the adherence rate for older drugs, shows a new analysis of medical records and insurance claims, according to news agency Reuters.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
